Our solid phase oligonucleotide synthesis services support biotech companies, pharmaceutical research teams, CROs, academic laboratories, and assay developers that need sequence-defined DNA, RNA, and chemically modified oligonucleotides produced with practical attention to synthesis feasibility, purification strategy, and downstream workflow fit. Solid-phase phosphoramidite chemistry remains the core manufacturing approach for custom oligonucleotides because it allows stepwise, programmable sequence assembly, controlled introduction of functional modifications, and flexible output from small screening quantities to larger research and process-support batches.
We combine sequence review, chemistry planning, solid-support selection, custom synthesis, deprotection strategy, purification design, and analytical release support to help clients move from sequence concept to usable material with fewer avoidable delays. Whether the project involves standard DNA primers, RNA oligos, phosphorothioate-containing constructs, labeled probes, conjugation-ready intermediates, or difficult long sequences, our team aligns chemistry choices with the actual technical purpose of the material. For projects requiring broader sequence sensitivity or challenging chemistry control, our Sensitive DNA/RNA Synthesis Platform and related workflow capabilities can be incorporated where appropriate.
Schematic of the solid-phase synthesis of PS oligonucleotides. (Yang et al., 2018)
Sequence-Dependent Coupling Loss: Each synthesis cycle must maintain strong coupling efficiency to preserve full-length product yield. Challenging base composition, repetitive motifs, and increasing chain length can reduce overall stepwise performance. We review sequence architecture early to reduce truncation risk and choose a more suitable synthesis plan.
Modification Compatibility: Many projects require more than standard DNA chemistry. Backbone changes, sugar modifications, terminal labels, spacers, and conjugation handles can alter deprotection behavior, purification difficulty, and final handling. Our team supports project-specific DNA/RNA modification planning so the target oligo is designed for both synthesis practicality and application value.
RNA and Sensitive Chemistry Control: RNA synthesis and certain modified oligos demand additional protection and deprotection logic, along with tighter moisture control and closer attention to side reactions. We build chemistry workflows that reflect the higher complexity of RNA, mixed-chemistry, and functionally sensitive constructs.
Purification and Analytical Fit: Desalting is not enough for every project. Some oligos require cartridge cleanup, HPLC, PAGE, or project-specific analytical review to separate target material from shortmers, failure sequences, and closely related impurities. We match purification and QC depth to intended use instead of applying a one-size-fits-all release plan.
Scale-Up and Downstream Integration: A sequence that works at screening scale may not behave the same way during larger-batch preparation, modification, or conjugation. Our services can connect synthesis with oligonucleotide conjugation services, labeling, and larger-scale process planning to improve continuity across development stages.
Our service portfolio is organized around the decisions customers actually need to make during oligonucleotide outsourcing: which chemistry to use, how to handle difficult sequences, which purification path fits the program, how to introduce modifications efficiently, and how to move from screening material to larger research supply without unnecessary workflow changes.
Instead of treating solid-phase oligonucleotide synthesis as a single generic service, we support fit-for-purpose project modules that cover standard synthesis, specialty chemistries, scale transitions, and downstream-ready oligo formats for research and development use.
This table helps technical and procurement teams compare common oligonucleotide project types, the synthesis considerations they introduce, and the release strategy questions that should be discussed before ordering.
| Project Type | Main Objective | Key Chemistry Considerations | Typical Purification Focus | Common Deliverable Priorities |
| Standard DNA Oligos | Produce reliable sequence-defined material for routine primers, probes, and controls | Base composition, sequence length, support loading, terminal format | Desalting or cartridge cleanup for lower-complexity projects; higher-purity methods where needed | Sequence accuracy, workable yield, clean integration into assay workflows |
| RNA Oligos | Deliver RNA sequences requiring additional protection and deprotection control | 2'-position protection strategy, moisture sensitivity, deprotection burden, handling stability | Higher attention to closely related impurities and deprotection-derived byproducts | Research-ready RNA material with practical storage and QC guidance |
| Modified Oligos | Add functional chemical properties while preserving sequence utility | Modification placement, reagent compatibility, linker choice, deprotection tolerance | Purification designed to separate target product from structurally similar modified impurities | Correct modification placement, identity confirmation, application fit |
| Long Oligos | Maintain acceptable full-length fraction as chain length and cycle count increase | Stepwise coupling loss, depurination risk, steric effects, sequence complexity | Higher-purity workflows often required because truncation burden rises with length | Feasible recovery of usable full-length material for downstream assembly or testing |
| Labeled or Handle-Bearing Oligos | Enable detection, capture, immobilization, or post-synthetic conjugation | Label chemistry, attachment site, hydrophobicity, synthesis and purification compatibility | Method selection based on label properties and removal of near-neighbor impurities | Functional labeling without compromising sequence integrity |
| Larger Research Batches | Supply more material without losing technical control over the process | Support format, reagent consumption, scale-dependent impurity burden, process consistency | Scalable purification and analytical review matched to batch role | Reproducibility, documentation continuity, and reliable material handoff |
Successful oligonucleotide outsourcing depends not only on the target sequence, but also on how individual synthesis and postsynthesis stages are controlled. The matrix below shows where technical review has the greatest impact on final material quality and project efficiency.
| Process Stage | Why It Matters | Typical Review Points | Risk If Under-Managed | Client Benefit |
| Support & Starting Chemistry | The solid support and initial attachment strategy affect accessibility, loading, and later cleavage behavior | Support type, pore environment, starting nucleoside or universal support logic, project scale | Poor accessibility, avoidable yield loss, or downstream process mismatch | Better technical fit before synthesis begins |
| Coupling Cycle | The full-length fraction depends on maintaining consistent cycle performance across the sequence | Activator choice, reagent quality, moisture control, difficult-sequence assessment | Truncation, deletion products, and lower usable yield | Higher confidence in target sequence recovery |
| Capping / Sulfurization / Oxidation | Backbone integrity and failure-sequence control depend on proper cycle completion chemistry | Standard oxidation versus sulfurization needs, capping completeness, mixed-chemistry compatibility | Heterogeneous product mixtures and more difficult purification | Cleaner product profile matched to target backbone design |
| Cleavage & Deprotection | Postsynthesis treatment must remove protecting groups without damaging sensitive motifs | Base protection scheme, RNA-specific handling, label stability, deprotection severity | Partial deprotection, degradation, or modification loss | Better preservation of intended structure and function |
| Purification Strategy | Different project types tolerate very different impurity profiles | Desalting versus HPLC versus PAGE, trityl status, impurity separation goals | Material that is technically delivered but poorly suited to the downstream experiment | Purity aligned with actual project use |
| Analytical Release | Clients need clear confirmation of what was synthesized and how it was assessed | Identity methods, purity evaluation, modification confirmation, reporting format | Ambiguous handoff, internal review delays, or unnecessary repeat ordering | Easier technical acceptance and smoother project continuation |
Our workflow is designed for customers who need more than simple sequence entry. We combine requirement review, chemistry planning, synthesis execution, and release support so that the delivered oligonucleotide fits the intended research task, not just the requested sequence text.
We review sequence information, target oligo type, intended use, desired scale, purity expectations, and any planned modifications or conjugation handles. This step helps define whether the project is routine, modified, long-sequence, or technically sensitive before chemistry is assigned.
Our team evaluates solid-phase feasibility, support format, likely cycle sensitivity, modification compatibility, RNA-specific handling needs, and expected purification burden. Project risks are identified early so the proposal reflects technical reality rather than a generic synthesis assumption.
The oligonucleotide route is organized around sequence composition, phosphoramidite selection, protection scheme, terminal functionality, and analytical goals. When needed, we also align the synthesis plan with later labeling, conjugation, or larger-batch continuation requirements.
Automated solid-phase synthesis is carried out with in-process attention to cycle consistency, reagent handling, and project-specific chemistry requirements. For more difficult sequences, additional process attention is used to improve the likelihood of recovering the desired full-length product.
After cleavage and deprotection, the product enters the agreed purification workflow and analytical review. Identity, purity, and modification-related checks are selected according to the role of the oligo, helping clients avoid overprocessing simple projects or undercharacterizing complex ones.
Final material is released with the agreed documentation package and delivered in a form suitable for downstream use. We can also support reorders, related sequence sets, scale progression, or connection to follow-on modification and conjugation workflows as the project develops.
Customers evaluating oligonucleotide partners usually need more than access to a synthesizer. They need a team that understands how sequence design, chemistry selection, purification, and project handoff interact in practice. Our service model is built to support those technical decisions clearly and commercially.
Solid-phase oligonucleotide synthesis enables a wide range of research and assay-development workflows where sequence control, modification flexibility, and reproducible material quality are essential. Our services are planned around practical application demands rather than generic oligo categories alone.
If your project involves custom DNA, RNA, modified oligonucleotides, long sequences, difficult motifs, or a scale transition that needs closer technical review, our team can help define a practical synthesis path before ordering moves forward. We work with research organizations that need clear communication on chemistry fit, purification strategy, analytical expectations, and downstream compatibility rather than generic sequence fulfillment alone. From early feasibility review to synthesis, purification, QC, and follow-on support, our platform is structured to help customers obtain oligonucleotide materials that are more usable in real laboratory workflows. Contact us to discuss your sequence, modification plan, target scale, and project requirements.
It's a method that builds DNA/RNA chains on a solid support through sequential nucleotide addition. This automated approach ensures high efficiency and purity for diverse applications.
It enables automated production with high coupling efficiency and easy impurity removal. The process supports scalable manufacturing from research to industrial quantities.
We provide backbone, sugar, and base modifications including phosphorothioate, 2'-OMe, and 2'-F. These enhance stability and functionality for specific applications.
We employ multiple analytical methods including HPLC, LC-MS, and CGE. Each batch undergoes rigorous purity and identity verification.
We utilize both controlled pore glass (CPG) and polystyrene (PS) carriers. The choice depends on scale requirements and specific modification needs.
